The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.
| Factor | Score | Distribution | Value | Avg | Verdict |
|---|---|---|---|---|---|
Valuation | 36 | — | 20.1x | Near average | |
Growth | 32 | -63.3% | 5.6% | Below average | |
Quality | 8 | -2557.5% | 7.6% | Below average | |
Safety | 59 | 2.8x | 0.4x | Near average | |
Capital Return | 41 | — | 2.19% | Near average | |
Momentum | — | — | — | No data | |
Sentiment | — | — | — | No data |
Immunome, Inc. is a publicly traded stock representing ownership in the company, giving holders rights to dividends and voting.
You can buy Immunome, Inc. shares through a licensed brokerage. Research the company's financials before investing.
Key metrics include Price-to-Earnings (P/E) ratio, Return on Equity (ROE), revenue growth, and net profit margin.
Dividend policies vary by company. Check the dividends section on the stock page for the payout history.
Risks include market volatility, sector-specific risks, regulatory changes, and company financial performance. Diversification helps reduce risk.
AI analysis from the earnings call, financials and news
This section combines price targets, revision history, analyst coverage changes, and an AI summary of what changed on the Street.
The price forecast for Immunome stock has seen positive stability with a slight upward trend, as the average target price rose from 36.20 to 36.33 dollars over the past thirty days. This stability reflects cautious optimism from the five analysts covering the stock, with a price dispersion ranging between 32 and 40 dollars, indicating a general consensus on the stock's intrinsic value despite the volatile nature of the sector.
Ten ratios that matter, each compared against its sector median and average — so you can see whether a number is rich or cheap relative to peers in the same sector.